Cantor Fitzgerald Maintains Overweight on Cerus, Raises Price Target to $4
$CERS
EDP Services
Technology
Cantor Fitzgerald analyst Ross Osborn maintains Cerus (NASDAQ:CERS) with a Overweight and raises the price target from $3 to $4.
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/12/2024 | $5.00 | Buy | Craig Hallum |
| 1/20/2023 | Buy → Neutral | BTIG Research | |
| 1/17/2023 | $3.75 | Overweight → Equal-Weight | Stephens |
Third Quarter and First Nine-Month Product Revenue Increased 16% and 18%, respectively from Prior Year Periods Raising Full-Year 2024 Total Product Revenue Guidance to the Range of $177 million to $179 million and INTERCEPT Fibrinogen Complex Revenue Guidance to a range of $9 to $10 million Cerus Corporation (NASDAQ:CERS) today announced financial results for its third quarter and nine months ended September 30, 2024. Total revenue for the three and nine months ended September 30, 2024 was comprised of (in thousands, except %): Three Months Ended Nine Months Ended September 30, Change September 30, Change 2024 2023 $
Cerus Corporation (NASDAQ:CERS) announced today that its third quarter 2024 financial results will be released on Wednesday, October 30, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A rep
Company to Host Conference Call and Webcast on Wednesday, October 16, 2024 at 5:00 p.m. EDT Cerus Corporation (NASDAQ:CERS) today announced updates on the INTERCEPT red blood cell (RBC) programs in the U.S. and in Europe: U.S. – New $248 million BARDA contract supports program beyond U.S. Phase 3 studies through anticipated PMA licensure and into commercialization Europe – CE Mark review has been concluded without approval; assessing strategy for anticipated future filing "We are pleased with the progress we have made with our U.S. RBC program, which will now receive additional support from BARDA through a new contract valued at up to $248 million, intended to fund activities includi
SC 13G/A - CERUS CORP (0001020214) (Subject)
SC 13G/A - CERUS CORP (0001020214) (Subject)
SC 13G/A - CERUS CORP (0001020214) (Subject)
4 - CERUS CORP (0001020214) (Issuer)
4 - CERUS CORP (0001020214) (Issuer)
4 - CERUS CORP (0001020214) (Issuer)
4 - CERUS CORP (0001020214) (Issuer)
4 - CERUS CORP (0001020214) (Issuer)
4 - CERUS CORP (0001020214) (Issuer)
Craig Hallum initiated coverage of Cerus with a rating of Buy and set a new price target of $5.00
BTIG Research downgraded Cerus from Buy to Neutral
Stephens downgraded Cerus from Overweight to Equal-Weight and set a new price target of $3.75
Cerus Corporation (NASDAQ:CERS) announced management participation in two upcoming investor conferences. Management plans to participate in the Stifel 2024 Healthcare Conference on Monday, November 18th at 4:10 PM ET, and will attend the Craig-Hallum Alpha Select Conference on Tuesday, November 19th. A live webcast of the Stifel 2024 Healthcare Conference will be available here and the replay will be available on the Company's website after the event. ABOUT CERUS Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital t
Third Quarter and First Nine-Month Product Revenue Increased 16% and 18%, respectively from Prior Year Periods Raising Full-Year 2024 Total Product Revenue Guidance to the Range of $177 million to $179 million and INTERCEPT Fibrinogen Complex Revenue Guidance to a range of $9 to $10 million Cerus Corporation (NASDAQ:CERS) today announced financial results for its third quarter and nine months ended September 30, 2024. Total revenue for the three and nine months ended September 30, 2024 was comprised of (in thousands, except %): Three Months Ended Nine Months Ended September 30, Change September 30, Change 2024 2023 $
Presentations Highlight the Unique Benefits of Real-world Utilization of INTERCEPT-treated Blood Products, Including INTERCEPT Fibrinogen Complex, and Recent Findings from the Phase 3 ReCePI Clinical Trial Cerus Corporation (NASDAQ:CERS) today announced a selection of abstracts to be presented at the 2024 Association for the Advancement of Blood & Biotherapies (AABB) Annual Meeting, taking place in Houston, Texas from October 19 through October 22. This year's AABB Annual Meeting attracts individuals and institutions from around the globe involved in the fields of transfusion medicine and biotherapies. The following is a select list of Cerus-related presentations and abstracts. All presen
U.S. stock futures were lower this morning, with the Nasdaq futures falling around 300 points on Wednesday. Shares of ASML Holding N.V. (NASDAQ:ASML) fell in today's pre-market trading following the release of second-quarter results. The Dutch company reported a second-quarter net income of 1.6 billion euros ($1.75 billion) on revenues of 6.2 billion euros ($6.77 billion), surpassing analysts' expectations of 1.41 billion euros on revenue of 6.04 billion euros, Reuters reported on Wednesday. The new bookings for the quarter stood at 5.6 billion euros ($6.11 billion), a significant increase from the 3.6 billion euros in the first quarter of 2024. ASML shares dipped 6.8% to $995.90 i
Shares of Bloom Energy Corporation (NYSE:BE) rose sharply in today's pre-market trading after the company announced a strategic partnership with CoreWeave. Bloom Energy said it entered into a partnership to deploy its proprietary fuel cells to generate on-site power for CoreWeave at a high-performance data center in Illinois. Bloom Energy shares jumped 12.1% to $16.90 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Shimmick Corporation (NASDAQ:SHIM) gained 53% to $3.09 in pre-market trading after the company received a $27.6 million subcontract for the Sunol Valley Water Treatment Plant Ozonation Project. Aptevo Therapeutics Inc. (NA
The Dow Jones index closed lower by over 80 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Earth Science Tech The Trade: Earth Science Tech, Inc. (OTC:ETST) Director Yovan Arturo Sanchez bought a total of 10,500 shares at an average price of $0.10. To acquire these shares, it cost around $1,050. What's Happening: On Jan. 29, Earth Scien
Cerus Corporation (NASDAQ:CERS) today announced the appointment of Dean Gregory to its Board of Directors. Mr. Gregory has a 30+-year career as a leader in the global blood transfusion and cell therapy industry, with broad experience across commercialization, product development, supply chain and manufacturing. For the last decade, Mr. Gregory served as President, Global Commercial Operations, Med Tech for Fresenius Kabi, the role from which he retired earlier this year. "We are very pleased to welcome Mr. Gregory to Cerus' Board of Directors," said Daniel Swisher, Chair of the Board. "Mr. Gregory brings a wealth of experience and expertise across the global transfusion medicine market, h
Cerus Corporation (NASDAQ:CERS) announced today that Alicia Goodman has been appointed to the role of Chief Human Resources Officer (CHRO). In this role, she will focus on sustaining and evolving the talent and organizational structure to support the future of the business as the leader in safeguarding the global blood supply. Ms. Goodman will also serve as a member of the Company's Executive Leadership Team. "We are excited to welcome Alicia to the Cerus team," said William "Obi" Greenman, Cerus' president and chief executive officer. "As we advance on key global commercial and pipeline initiatives, our talent, leadership and organization structure across all levels of the organization w
Cerus Corporation (NASDAQ:CERS) today announced the appointment of Hua Shan, MD, PhD, Professor of Pathology and Medical Director, Transfusion Medicine Service at Stanford Medical Center to its Board of Directors. "We are pleased to welcome Dr. Shan to Cerus' Board of Directors," said Daniel Swisher, Chair of the Board. "Dr. Shan is an accomplished, leading voice in the transfusion community, with more than twenty-five years of experience in the field, bringing a wealth of knowledge and insight to our Board. In addition, Dr. Shan has extensive experience with international blood bank practices including the Chinese transfusion market. We expect to benefit from Dr. Shan's expertise as we co
10-Q - CERUS CORP (0001020214) (Filer)
8-K - CERUS CORP (0001020214) (Filer)
8-K - CERUS CORP (0001020214) (Filer)